Time Cap Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 4.16 M
as on 16-12-2024
- Company Age 36 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.08 Cr
as on 16-12-2024
About Time Cap Pharma Labs
The Corporate was formerly known as Time Cap Pharma Labs Ltd. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.16 M.
The company currently has active open charges totaling ₹3.08 Cr.
Venkata Kantamani, Adinarayana Madineedi, Sadasiva Nannapaneni, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232TG1988PTC008333
- Company No.
008333
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Feb 1988
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- LocationHyderabad, Telangana
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Time Cap Pharma Labs?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Kantamani  | Whole-Time Director | 30-Sep-2024 | Current |
| Adinarayana Madineedi | Director | 31-Jan-2019 | Current |
| Sadasiva Nannapaneni | Director | 30-Apr-2009 | Current |
| Anand Tummala | Director | 29-Apr-2000 | Current |
Financial Performance and Corporate Structure Insights of Time Cap Pharma Labs.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Time Cap Pharma Labs?
Unlock access to Time Cap Pharma Labs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Natco Power Private LimitedActive 9 years 5 monthsVenkata Kantamani and Sadasiva Nannapaneni are mutual person
- Natco Drug Discovery Private LimitedActive 35 years 7 months
Sadasiva Nannapaneni is a mutual person
- Natsoft Information Systems Private LimitedActive 26 years 4 months
Sadasiva Nannapaneni is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Oriental Bank Of Commerce Creation Date: 09 Dec 1994 | ₹1.40 Cr | Open |
Oriental Bank Of Commerce Creation Date: 28 Dec 1992 | ₹1.68 Cr | Open |
How Many Employees Work at Time Cap Pharma Labs?
Unlock and access historical data on people associated with Time Cap Pharma Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Time Cap Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Time Cap Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
